<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159741</url>
  </required_header>
  <id_info>
    <org_study_id>GA-8-2017</org_study_id>
    <nct_id>NCT03159741</nct_id>
  </id_info>
  <brief_title>Investigation of GLP-2 Mechanism of Action</brief_title>
  <official_title>Investigation of GLP-2 Mechanism of Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation
      in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit
      the bone resorption. However, the mechanism is unknown. In the present study we will
      investigate the mechanism of action using a receptor specific inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-terminal telopeptide (CTX)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>Marker of bone resorption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-terminal propeptide of type 1 procollagen (P1NP)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>Marker of bone formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin (OC)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>Bone marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone (PTH)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>Bone marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoprotegerin (OPG)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>Bone marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>-30 to 240 min.</time_frame>
    <description>GIP total and intact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glukagon-like peptide-1 (GLP-1) and glukagon-like peptide-2 (GLP-2)</measure>
    <time_frame>-30 to 240 min.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glukagon and pancreatic polypeptide (PP)</measure>
    <time_frame>-30 to 240 min.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>-30 to 240 min.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin/c-pep.</measure>
    <time_frame>-30 to 240 min.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Inhibitor + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + GIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inhibitor + GLP-2</intervention_name>
    <description>Inhibitor and GLP-2 are used as study tools.</description>
    <arm_group_label>Inhibitor + GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + GLP-2</intervention_name>
    <description>Placebo and GLP-2 are used as study tools.</description>
    <arm_group_label>Placebo + GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + GIP</intervention_name>
    <description>Placebo and GIP are used as study tools.</description>
    <arm_group_label>Placebo + GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo + Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, 20 to 40 years old, caucasian, BMI 18,5 to 24,9 kg/m2

        Exclusion Criteria:

          -  Chronic disease, smoking, medication, weight change more than 3 kg whitin the last 3
             months, overweight surgery, intestinal surgery, Hgb&lt;8,0 mmol/L, decreased renal
             function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Rosenkilde, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sten Madsbad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsa Skov</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

